Meeting
2018 Genitourinary Cancers Symposium
Primary resistance in docetaxel and androgen deprivation therapy in metastatic castrate sensitive prostate cancer patients.
Authors
Athanasios Pouptsis
Guy's and St Thomas' Hospital NHS Foundation Trust, London, United Kingdom
Athanasios Pouptsis , Styliani Germanou , Nick Waldron , Thomas Young , Madeha Khan , Simon Hughes , Debra Hannah Josephs , Sarah Maria Rudman , Deborah Enting , Simon Chowdhury
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, and Testicular Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 342)
DOI
10.1200/JCO.2018.36.6_suppl.342
Abstract #
342
Poster Bd #
D11
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
Treatment outcomes for metastatic castrate-resistant prostate cancer (mCRPC) patients (pts) following docetaxel (D) for hormone sensitive disease.
First Author: Andrew Lachlan Schmidt
Poster
2020 Genitourinary Cancers Symposium
Radium-223 in the treatment of metastatic castrate-resistant prostate cancer: A real-world Irish experience.
First Author: Niamh Peters
Poster
2019 Genitourinary Cancers Symposium
Radium 223 treatment in metastatic castrate-resistant prostate cancer: Impact of sequencing on survival—Real-world outcomes from a single UK centre.
First Author: Xue Yan Jiang
Poster
2018 Genitourinary Cancers Symposium
Real-world experience with docetaxel for castration-sensitive prostate cancer from a population-based analysis.
First Author: Jean-Michel Lavoie